VANCOUVER, British Columbia, Feb. 22, 2011 /PRNewswire/ — Enox
Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the
IN3 West Investment in Innovation Conference on Thursday, February
24 at 11:05 AM PST. The conference is being held at the Venetian
Hotel in Las Vegas.
Dr. Rewcastle will provide an overview of Enox’s technology and
its ability to embed nitric oxide into polymer medical devices
rendering them antimicrobial. He will also review recently
published independent data that shows that ionic silver coatings
for medical devices are not as effective as hoped.
“There is a very significant clinical need for an effective
non-antibiotic treatment to render medical devices antimicrobial,”
said Rewcastle. “Each year in the United States alone, hospital
acquired infections kill hundreds of thousands of patients and cost
the health care system tens of billions of dollars. Silver coatings
were hoped to be an answer to increasing antibiotic but, based on
recent publications, this does not appear to be the case. Our
nitric oxide technology is uniquely positioned to answer this
critical need of all healthcare systems worldwide.”
“The IN3 West Conference is an ideal venue for Enox to present
at,” continued Rewcastle. “The participants consist of both venture
capitalists and larger companies seeking to partner with emerging
technologies. I am looking forward to the meeting and expect a very
positive response.”About Enox Biopharma Inc.Enox Biopharma, Inc. is
an emerging biotechnology company with proprietary technology that
embeds nitric oxide (NO) into polymer medical devices. The innate
immune system uses NO to block microbial growth – embedding NO into
medical devices makes them antimicrobial. Enox’s technology is
applicable to any indwelling polymer medical device including, but
not limited to catheters, endotracheal tubes, tympanostomy tubes
and cosmetic implants. With the current CMS non-coverage of certain
nosocomial infections
‘/>”/>
